Skip to main content
Company News
juin 25, 2021

This morning, Dr Weiss presented our Phase 3 data at @EASL | The Home of Hepatology’s International Liver Congress 2021.

Positive top-line data announced from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine at EASL’s International Liver Congress 2021.

Friday 25 June

Today we are excited to announce positive top-line data from our Phase 3 head-to-head trial of trientine tetrahydrochloride and d-penicillamine.

This is the first trial of its kind comparing against the only approved first-line treatment of Wilson’s Disease, d-penicillamine, in more than 70 years.

Dr Karl Heinz Weiss will be presenting this data today at 8.45–9am CEST as part of @EASL | The Home of Hepatology’s International Liver Congress 2021.

Healthcare Professionals

The page you are about to enter is intended for Healthcare Professionals. Please confirm that you are a Healthcare Professional.

Cancel